Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in Malignant Pleural Mesothelioma
NCT01024946Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2009
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of everolimus in malignant pleural mesothelioma (MPM) and malignant peritoneal mesothelioma (MPM), sponsored by Memorial Sloan Kettering Cancer Center. Started Dec 2009; status: completed.
02
Drugs
everolimus
03
Conditions
malignant pleural mesothelioma (MPM)malignant peritoneal mesothelioma (MPM)
Beyond the preview
Go deeper on NCT01024946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01024946.